Last reviewed · How we verify
Addition of clarithromycin to rifampicin and ethambutol
Addition of clarithromycin to rifampicin and ethambutol is a Small molecule drug developed by British Thoracic Society. It is currently FDA-approved.
At a glance
| Generic name | Addition of clarithromycin to rifampicin and ethambutol |
|---|---|
| Sponsor | British Thoracic Society |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD) (PHASE2, PHASE3)
- Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection (PHASE2)
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study (PHASE4)
- Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease (PHASE2)
- Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Addition of clarithromycin to rifampicin and ethambutol CI brief — competitive landscape report
- Addition of clarithromycin to rifampicin and ethambutol updates RSS · CI watch RSS
- British Thoracic Society portfolio CI
Frequently asked questions about Addition of clarithromycin to rifampicin and ethambutol
What is Addition of clarithromycin to rifampicin and ethambutol?
Addition of clarithromycin to rifampicin and ethambutol is a Small molecule drug developed by British Thoracic Society.
Who makes Addition of clarithromycin to rifampicin and ethambutol?
Addition of clarithromycin to rifampicin and ethambutol is developed and marketed by British Thoracic Society (see full British Thoracic Society pipeline at /company/british-thoracic-society).
What development phase is Addition of clarithromycin to rifampicin and ethambutol in?
Addition of clarithromycin to rifampicin and ethambutol is FDA-approved (marketed).